September 14, 2011 – The Delaware Insurance Commissioner’s announcement that Blue Cross Blue Shield of Delaware (BCBSD) will support physicians’ use of an American College of Cardiology (ACC) program to make decisions about certain diagnostic imaging tests is a win for patients and a win for quality-of-care, said ACC CEO Jack Lewin, M.D.

Commissioner Karen Weldin Stewart on Tuesday announced an agreement with BCBSD that the company will pay for Delaware physicians to participate in the ACC’s online appropriate-use criteria-based program, FOCUS: Cardiovascular Imaging Strategies. The program supports physician decision-making and the use of best practices for decisions regarding cardiovascular diagnostic imaging. The agreement followed a state review of patient complaints about practices related to pre-authorization for nuclear cardiac imaging tests and concerns raised in the report about differences in criteria used by physician and insurers for nuclear cardiac imaging tests.

“In order to solve this problem, we need to get everyone on the same page as to when the studies are appropriate,” Stewart said in announcing the agreement. “With this new program, BCBSD is using the best criteria developed by the expert physicians, the American College of Cardiology, and will pay to have Delaware physicians using the best medical criteria.”  

FOCUS uses a computer-based tool developed by the ACC to help guide physicians when ordering imaging tests.  The tool applies nationally accepted, transparent and physician-developed appropriate use criteria to guide ordering of nuclear cardiac imaging tests. FOCUS allows local physicians to consistently apply appropriate use criteria to determine when patient tests are needed.  Importantly, the program provides feedback reports on the patterns of appropriate use to physician practices and health plans.  FOCUS participants then use the reports to complete action plans and share best practices.

“This decision is a win for patients and a win for evidence-based medicine,” Lewin said. “Commissioner Stewart and her staff should be commended for providing a solution that is based on physician-developed appropriate use criteria. This type of approach results in better care for patients and can ultimately save money. We hope Delaware will be a model for managing medical costs by focusing on patient-centered decision making and quality care.”

For more information: www.cardiosource.org/focus

 


Related Content

News | Computed Tomography (CT)

SPONSORED CONTENT — Fujifilm’s latest CT technology brings exceptional image quality to a compact and user- and patient ...

Time August 06, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
Feature | Computed Tomography (CT) | By Melinda Taschetta-Millane

In the ever-evolving landscape of medical imaging, computed tomography (CT) stands out as a cornerstone technology ...

Time July 30, 2024
arrow
News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
Feature | Radiology Business | By Christine Book

Across the healthcare industry, and, notably, throughout the radiology community in just the past few years, the focus ...

Time July 26, 2024
arrow
Feature | Mobile C-Arms | By Melinda Taschetta-Millane

Mobile C-arms continue to revolutionize medical imaging, offering versatility, mobility and real-time visualization ...

Time July 26, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
Subscribe Now